News
-
-
-
-
PRESS RELEASE
Psycheceutical Bioscience Strategically Pivots Into the Brain-Computer Interface (BCI) Space
Psycheceutical Bioscience, Inc. appoints Neilank K. Jha, MD, as Executive Chairman and CEO to lead a turnaround, shifting focus from the psychedelic space to Brain-Computer Interface (BCI) technology. The company's mission is to develop products to improve the quality of life and survival rate of patients with neurological conditions. With partnerships with top-tier academic institutions and a prototype smart medical device in development, the company aims to revolutionize neurological therapies. The Board is exploring options to cure regulatory filing deficiencies and enable future corporate actions. NeuraSeed BCI, the next-generation neuroscience company, is focused on deep-brain implantation technology and brain-computer interfaces, aiming to transform neurological therapies for global benefit. -
-
-
-
-
